Cargando…

Pathogenic potential of antibodies to the GABA(B) receptor

GABA(B) receptor (GABA(B)R) autoantibodies have been detected in the serum of immunotherapy‐responsive patients with autoimmune encephalitis. This study aimed to investigate the effect of immunoglobulin G (IgG) from a patient with GABA(B)R antibodies on primary neuronal cultures and acute slices of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nibber, Anjan, Mann, Edward O., Pettingill, Philippa, Waters, Patrick, Irani, Sarosh R., Kullmann, Dimitri M., Vincent, Angela, Lang, Bethan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862107/
https://www.ncbi.nlm.nih.gov/pubmed/29588966
http://dx.doi.org/10.1002/epi4.12067
_version_ 1783308171790516224
author Nibber, Anjan
Mann, Edward O.
Pettingill, Philippa
Waters, Patrick
Irani, Sarosh R.
Kullmann, Dimitri M.
Vincent, Angela
Lang, Bethan
author_facet Nibber, Anjan
Mann, Edward O.
Pettingill, Philippa
Waters, Patrick
Irani, Sarosh R.
Kullmann, Dimitri M.
Vincent, Angela
Lang, Bethan
author_sort Nibber, Anjan
collection PubMed
description GABA(B) receptor (GABA(B)R) autoantibodies have been detected in the serum of immunotherapy‐responsive patients with autoimmune encephalitis. This study aimed to investigate the effect of immunoglobulin G (IgG) from a patient with GABA(B)R antibodies on primary neuronal cultures and acute slices of entorhinal cortex. Primary hippocampal neuronal cultures were incubated with serum immunoglobulin from patients with GABA(B)R or AMPA receptor (AMPAR) antibodies for up to 72 h to investigate their effect on receptor surface expression. Whole‐cell patch‐clamp recordings from layer III pyramidal cells of the medial entorhinal cortex were used to examine the effect on neuronal activity. GABA(B)R surface expression was unaltered by incubation with GABA(B)R antibodies. By contrast, after 24 h application of AMPAR antibodies, AMPARs were undetectable. However, acute application of GABA(B)R IgG decreased both the duration of network UP states and the spike rate of pyramidal cells in the entorhinal cortex. GABA(B)R antibodies do not appear to affect GABA(B)Rs by internalization but rather reduce excitability on the medial temporal lobe networks. This unusual mechanism of action may be exploited in rational drug development strategies.
format Online
Article
Text
id pubmed-5862107
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58621072018-03-27 Pathogenic potential of antibodies to the GABA(B) receptor Nibber, Anjan Mann, Edward O. Pettingill, Philippa Waters, Patrick Irani, Sarosh R. Kullmann, Dimitri M. Vincent, Angela Lang, Bethan Epilepsia Open Short Research Article GABA(B) receptor (GABA(B)R) autoantibodies have been detected in the serum of immunotherapy‐responsive patients with autoimmune encephalitis. This study aimed to investigate the effect of immunoglobulin G (IgG) from a patient with GABA(B)R antibodies on primary neuronal cultures and acute slices of entorhinal cortex. Primary hippocampal neuronal cultures were incubated with serum immunoglobulin from patients with GABA(B)R or AMPA receptor (AMPAR) antibodies for up to 72 h to investigate their effect on receptor surface expression. Whole‐cell patch‐clamp recordings from layer III pyramidal cells of the medial entorhinal cortex were used to examine the effect on neuronal activity. GABA(B)R surface expression was unaltered by incubation with GABA(B)R antibodies. By contrast, after 24 h application of AMPAR antibodies, AMPARs were undetectable. However, acute application of GABA(B)R IgG decreased both the duration of network UP states and the spike rate of pyramidal cells in the entorhinal cortex. GABA(B)R antibodies do not appear to affect GABA(B)Rs by internalization but rather reduce excitability on the medial temporal lobe networks. This unusual mechanism of action may be exploited in rational drug development strategies. John Wiley and Sons Inc. 2017-07-19 /pmc/articles/PMC5862107/ /pubmed/29588966 http://dx.doi.org/10.1002/epi4.12067 Text en © 2017 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Research Article
Nibber, Anjan
Mann, Edward O.
Pettingill, Philippa
Waters, Patrick
Irani, Sarosh R.
Kullmann, Dimitri M.
Vincent, Angela
Lang, Bethan
Pathogenic potential of antibodies to the GABA(B) receptor
title Pathogenic potential of antibodies to the GABA(B) receptor
title_full Pathogenic potential of antibodies to the GABA(B) receptor
title_fullStr Pathogenic potential of antibodies to the GABA(B) receptor
title_full_unstemmed Pathogenic potential of antibodies to the GABA(B) receptor
title_short Pathogenic potential of antibodies to the GABA(B) receptor
title_sort pathogenic potential of antibodies to the gaba(b) receptor
topic Short Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862107/
https://www.ncbi.nlm.nih.gov/pubmed/29588966
http://dx.doi.org/10.1002/epi4.12067
work_keys_str_mv AT nibberanjan pathogenicpotentialofantibodiestothegababreceptor
AT mannedwardo pathogenicpotentialofantibodiestothegababreceptor
AT pettingillphilippa pathogenicpotentialofantibodiestothegababreceptor
AT waterspatrick pathogenicpotentialofantibodiestothegababreceptor
AT iranisaroshr pathogenicpotentialofantibodiestothegababreceptor
AT kullmanndimitrim pathogenicpotentialofantibodiestothegababreceptor
AT vincentangela pathogenicpotentialofantibodiestothegababreceptor
AT langbethan pathogenicpotentialofantibodiestothegababreceptor